BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

On the pharma side, Eric Sagonowsky and Kevin Dunleavy ... the nuances of the current commercial landscape. Later, Fierce Biotech's Gabrielle Masson and Darren Incorvaia highlight key data from ...

The proteose peptone sector has experienced strategic consolidation through mergers and acquisitions. Major life sciences ... solutions in vaccine and antibiotic production. Global pharmaceutical R&D ...

The Big Pharma has penned a deal to acquire SiteOne ... according to a Feb. 4 release. The Bay Area biotech closed a $100 million series C fundraise led by Novo Holdings at the end of last year ...

Sanofi to acquire Vigil Neuroscience for up to $600M, including a $2/share CVR tied to VG-3927 milestones. VG-3927, a once-daily oral TREM2 agonist for Alzheimer’s, to enter Phase 2; VGL101 ...